Nippon India Pharma Fund - Direct (G) vs SBI Corporate Bond Fund - Direct (G)

Nippon India Pharma Fund - Direct (G) vs SBI Corporate Bond Fund - Direct (G)

stock1

Nippon India Pharma Fund - Direct (G)

7.4%

stock2

SBI Corporate Bond Fund - Direct (G)

5.14%

Loading chart...

About Fund

Deutsche Bank AG

Karvy Computershare Pvt. Ltd.

Citi Bank HDFC Bank Ltd. Stock Holding Corporation of India

Computer Age Management Services Pvt. Ltd Computronics Financial Services India Ltd Datamatics Financial Software Services Ltd

Very High Risk

5000

9044.23

1.12

634.5023

January 1, 2013

1

Low to Moderate Risk

5000

22160.90

0.81

16.9779

January 16, 2019

0

14.01 %

19.35 %

7.4 %

6.4 %

7.43 %

5.14 %

Sailesh Raj Bhan

MBA (Finance), CFA.

Mr.Bhan is an MBA with specialization in Finance and CFA. Has over 9 Yrs. of experience in Equity Securities Research & Sequeir Investment Pvt. Ltd. for 5 years and with Emkay Share & stock Broker Pvt. Ltd. for 2 years.

Rajeev Radhakrishnan

B.E. (Production), MMS (Finance), Cleared Level 2 of the CFA exam conducted by CFA Institute, USA.

Total experience of 17 years in funds management. Around 8 years in Fixed Income funds management and dealing. Previously he was associated with UTI Asset Management Company Ltd. as Co - Fund Manager Past experiences: SBI Funds Management P. Ltd - (From June 09, 2008 onwards) Co- Fund Manager - UTI Asset Management Company Limited (June 2001-2008)

Get your FAQs right